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Abstract
Background: Alpha-Synuclein (α-syn), a 140 amino acid protein associated with presynaptic
membranes in brain, is a major constituent of Lewy bodies in Parkinson's disease (PD). Three
missense mutations (A30P, A53T and E46K) in the α-syn gene are associated with rare autosomal
dominant forms of familial PD. However, the regulation of α-syn's cellular localization in neurons
and the effects of the PD-linked mutations are poorly understood.
Results: In the present study, we analysed the ability of cytosolic factors to regulate α-syn binding
to synaptic membranes. We show that co-incubation with brain cytosol significantly increases the
membrane binding of normal and PD-linked mutant α-syn. To characterize cytosolic factor(s) that
modulate α-syn binding properties, we investigated the ability of proteins, lipids, ATP and calcium
to modulate α-syn membrane interactions. We report that lipids and ATP are two of the principal
cytosolic components that modulate Wt and A53T α-syn binding to the synaptic membrane. We
further show that 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine (C16:0 PAF) is one of the
principal lipids found in complex with cytosolic proteins and is required to enhance α-syn
interaction with synaptic membrane. In addition, the impaired membrane binding observed for
A30P α-syn was significantly mitigated by the presence of protease-sensitive factors in brain
cytosol.
Conclusion: These findings suggest that endogenous brain cytosolic factors regulate Wt and
mutant α-syn membrane binding, and could represent potential targets to influence α-syn solubility
in brain.
Published: 22 September 2008
BMC Neuroscience 2008, 9:92 doi:10.1186/1471-2202-9-92
Received: 6 May 2008
Accepted: 22 September 2008
This article is available from: http://www.biomedcentral.com/1471-2202/9/92
© 2008 Wislet-Gendebien et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Neuroscience 2008, 9:92 http://www.biomedcentral.com/1471-2202/9/92
Page 2 of 16
(page number not for citation purposes)
Background
The synuclein family of intrinsically unfolded proteins is
composed of three homologous and evolutionarily-con-
served members with poorly defined physiological roles
[1]. Of these, α-synuclein (α-syn) has gained particular
prominence due to its abundance in nerve terminals and
its association with multiple neurodegenerative disorders
including Parkinson disease (PD) [2]. α-Syn behaves as a
peripherally associated membrane protein and can stably
interact with synthetic phospholipid vesicles containing
negatively charged head groups [3] via its amino-terminal
domain, an amphipathic region comprising almost two-
thirds of the protein and containing seven copies of an 11-
residue repeat sequence [4]. Whereas the freely diffusible
form of α-syn is natively unfolded, the N-terminal repeat
region adopts an α-helical conformation upon binding to
artificial vesicles and detergent micelles [3]. Numerous
studies have revealed that the interaction of α-syn with
phospholipid membranes, fatty acids, or detergent
micelles alters the kinetics of its aggregation [4-9]. We and
others have previously reported that synaptic α-syn in vivo
is partitioned between both cytosolic and membrane-
bound fraction [10-14]. However, despite the understand-
ing of the conformational properties of membrane-bound
α-syn, the biochemical mechanisms that mediate α-syn
interaction with biological membranes are poorly under-
stood, thereby limiting our understanding of α-syn's
physiological role, as well as potential therapeutic
approaches to moderate its misfolding and aggregation in
disease.
In this study, we developed an in vitro assay to characterise
the factor(s) involved in α-syn's binding to synaptic mem-
branes (Figure 1A). Using this assay, we analysed the
effects of cytosolic proteins, lipids, ATP and calcium on
the modulation of α-syn membrane association. Our
results revealed that ATP and lipids are two of the princi-
pal cytosolic components that modulate the α-syn bind-
ing to synaptic membranes. In addition, we report here
that the binding of A30P α-syn to synaptic membranes
improves significantly in the presence of endogenous
cytosolic protein(s) and that the lower recovery of mem-
brane bound A30P is likely due to a more transient inter-
action which can be stabilised by artificial cross-linking.
Methods
Synaptosome preparation
Synaptosomes were prepared as described (Fischer von
Mollard et al. 1991;Tandon et al. 1998a). Briefly, the cer-
ebral cortices from mice α-syn KO mice were dissected
and homogenized with 10 strokes at 500 rpm, in ice-cold
buffer A (320 mM sucrose, 1 mM EGTA, and 5 mM HEPES
[pH 7.4]). The homogenate was centrifuged at 1000 × g
for 10 min. Next, the supernatant was spun for 10 min at
24000 × g and the resulting pellet (P2) resuspended in
buffer A. The P2 fraction was loaded onto a discontinuous
FICOLL gradient (13%, 9%, 5% in buffer A) and centri-
fuged for 35 min at 35,000 × g. The 13%-9% interface,
containing intact synaptosomes, was resuspended in
buffer B (140 mM NaCl, 5 mM KCl, 20 mM HEPES, 5 mM
NaHCO3, 1.2 mM Na2HPO4, 1 mM MgCl2, 1 mM EGTA,
and 10 mM glucose). The sample was spun at 24000 × g
for 10 min and the pellet was washed two times in buffer
C (10 mM HEPES, 18 mM KOAc, [pH 7.2]), then spun at
24000 × g for 10 min and resuspended in buffer D (25
mM HEPES, 125 mM KoAc and 2.5 mM MgCl2). After cen-
trifugation (24000 × g for 10 min), synaptosomes were
resuspended in buffer D and were incubated with or with-
out brain α-syn KO cytosol. Samples were incubated for
10 min at 37°C before separating membrane and super-
natant by centrifugation at 24000 × g for 10 min. α-syn
binding was quantified by western blotting.
Cytosol preparation
Mouse brains were thoroughly homogenized in 85 mM
sucrose, 100 mM KOAc, 1 mM MgOAc, and 20 mM
HEPES (pH 7.4). The homogenate was centrifuged for 10
min at 15,000 × g and the supernatant spun for 1 hr at
100,000 × g. The supernatant was subsequently dialyzed
for 4 hr in 145 mM KOAc and 25 mM HEPES (pH 7.2)
and frozen at -80°C. Protein concentration was deter-
mined by BCA protein assay (Pierce, Biolynx Inc., Can-
ada).
Lipid-free cytosol preparation
Chloroform was added to the cytosol (v/v), vigorously
vortexed and incubated for 30 min at room temperature.
After centrifugation for 10 min at 14000 × g, two phases
were obtained: upper phase (TOP) containing the gan-
gliosides or small organic molecules, the interphase con-
taining the proteins and the lower phase containing the
lipids. In some experiments, 1-O-hexadecyl-2-acetyl-sn-
glycero-3-phosphocholine (C16:0 PAF, Biomol) was
added alone or directly to delipidated cytosol to test effect
on α-syn membrane binding.
Cytosol digestion
Cytosol digestion was done with trypsin or Proteinase K
and proteolytic activity was terminated with trypsin inhib-
itor or PMSF, respectively prior to the incubation with
membranes. The enzyme inhibition was controlled by a
partial rescue of the digested cytosol after half-dilution
with untreated cytosol.
Expression and Purification of Recombinant α-synuclein
Human Wt α-syn cDNAs were subcloned into the plasmid
pET-28a (Novagen), using Nco I and Hind III restriction
sites. α-Syn was overexpressed in Escherichia coli BL21
(DE3) via an isopropyl-1-thio-3/4-D-galactopyranoside-
inducible T7 promoter. The bacterial pellet was resus-BMC Neuroscience 2008, 9:92 http://www.biomedcentral.com/1471-2202/9/92
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pended in phosphate buffered saline (PBS) containing 1
mM phenylmethylsulfonyl fluoride (PMSF). The bacterial
suspension was then sonicated for 30 sec several times,
boiled for 15 min, and ultracentrifuged at 150,000 × g for
30 min. The supernatant containing the heat-stable α-syn
was dialyzed against 50 mM Tris, pH 8.3, loaded onto a
Q-Sepharose column (Pharmacia Biotech), and eluted
with a 0–500 mM NaCl step-gradient. The eluents were
desalted and concentrated on a Centricon-10 (Millipore)
in 5 mM phosphate buffer, pH 7.3. Aliquots of each puri-
fication step were analyzed by SDS-polyacrylamide gel
electrophoresis (PAGE) to confirm purity. Protein concen-
tration was determined by Lowry assay.
Western blotting
Proteins were boiled briefly in loading buffer (glycerol
10% v/v; Tris 0.05 M pH 6.8; SDS 2%, bromophenol blue
and 2.5% v/v β-mercaptoethanol) and separated by elec-
(A) α-syn binding assay Figure 1
(A) α-syn binding assay. Step 1. Synaptosomes are prepared from α-syn-/- mice and α-syn (human Wt and PD-linked A30P 
and A53T forms) is expressed and purified from E. coli. Step 2. Synaptic membranes (α-syn acceptor fraction) are prepared 
from intact synaptosomes using hypotonic buffer and incubated with purified α-syn (donor fraction) in presence or absence of 
α-syn-/- (KO) cytosol. Step 3. Membrane and cytosol fractions are separated by centrifugation and the membrane proteins are 
analysed by western blotting. (B) Using the binding assay, KO synaptic membranes were incubated, for 10 min at 37°C, with 3 
μg of Wt, A30P or A53T purified α-syn in absence or presence of 1.5 mg/ml of KO cytosol. As shown on this graph, A30P 
purified α-syn has a lower binding compared to Wt and A53T α-syn in absence (One-Way ANOVA, p < 0.0001, n = 4; Bonfer-
roni's multiple comparison test) or presence (One-Way ANOVA, p < 0.0001, n = 4; Bonferroni's multiple comparison test) of 
KO cytosol. (C) KO synaptic membranes were incubated, for 10 min at 37°C, with 0.1, 0.6 and 3 μg of Wt, A30P or A53T 
purified α-syn in absence or presence of 1.5 mg/ml of KO cytosol. Results are normalized to the maximal binding observed for 
each respective α-syn. These data show that the cytosol has a significant effect by increasing the binding of all types of α-syn 
(One-Way ANOVA: Wt: p < 0.0001, n = 4; A30P: p < 0.0001, n = 4; A53T p < 0.001, n = 4).BMC Neuroscience 2008, 9:92 http://www.biomedcentral.com/1471-2202/9/92
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trophoresis using 12% Tris-glycine polyacrylamide gels.
Proteins were transferred to nitrocellulose (Life Sciences)
and probed by western blotting using: antibodies against
α-syn (monoclonals 211 and Syn-1 at 1:1000, Neomark-
ers), our own rabbit polyclonal (LWS1, 1:1000) raised to
a 24-mer α-syn-specific peptide, or synaptophysin
(Mouse monoclonal antibody, dilution 1:10000, Biode-
sign International). Bound HRP-conjugated anti-mouse
or anti-rabbit IgG (Sigma) were revealed by chemilumi-
nescence using ECL Plus (GE Healthcare) and quantified
with a Storm 860 fluorescent imager and ImageQuant
software (Molecular Dynamics). Statistical comparisons
were calculated with GraphPad InStat software using Stu-
dent's T-test for comparisons between two groups or
ANOVA (Bonferroni test) for multiple comparisons.
Synaptic lipid raft preparation
Lipid rafts were prepared from the synaptosomes or syn-
aptic membrane isolated from cortices as described above.
Synaptosomes or synaptic membrane were resuspended
in 25 mM MES, pH 6.5, 50 mM NaCl, 1 mM NaF, 1 mM
Na3VO4, and 1% TX-100 (lysis buffer) supplemented
with phosphatase inhibitor cocktails (Sigma) and incu-
bated on ice for 30 min with Dounce homogenization
every 10 min. The cell lysate was then adjusted to 42.5%
sucrose, overlayed with 35 and 5% sucrose in lysis buffer
without TX-100 and sedimented at 275,000 × g for 18 hr
at 4°C. Fractions were collected from the top of the gradi-
ent and stored at -80°C. Equal volumes of each fraction
were separated by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and probed with the dif-
ferent antibodies as described above. Lipid raft-containing
fractions were identified by the presence of flotillin-1 (BD
Biosciences, Canada).
Glycerophospholipid extraction
C13:0 lysophosphatidylcholine (C13:0 LPC) and 1-O-
hexadecyl-2-[2H4]acetyl-glycerophosphocholine (d4-16:0
PAF) were purchased from Avanti Polar Lipids (Alabaster,
AL). Stock chemicals were purchased from J.T. Baker
(Phillipsburg, NJ) with the exception of bovine serum
albumin (BSA) from Sigma (St. Louis, MO). Glycerophos-
pholipids were extracted according to a modified Bligh/
Dyer procedure [15] as we have previously published[16].
Briefly, lipids were extracted using a volumetric ratio of
0.95 of chloroform and 0.8 of 0.1 M Na acetate (aq) per
volume of MeOH in acid-washed borosilicate glass tubes
(Fisher, Ottawa, ON). Phospholipids were collected from
the organic phase after layer separation by centrifugation.
The aqueous phase was back-extracted three times in the
organic phase of a wash solution prepared by combining
RPMI+ 0.025% BSA, methanol, chloroform, and sodium
acetate in the volumetric ratio of 1:2.5:3.75:1. The organic
fractions were combined, evaporated under a stream of
nitrogen gas, and dissolved in 300 μl EtOH. C13:0 lyso-
phosphatidylcholine (C13:0 LPC), a lipid not naturally
occurring in mammalian cells [17], was spiked into
cytosol preparations at a concentration of 189 ng prior to
extraction to control for variation in extraction efficiency.
LC-ESI-MS
Glycerophospholipids were analyzed as we have
described previously [16]. Briefly, extracts were diluted
1:4 in EtOH with 13 μL of diluent brought to 40 μl with
0.1% formic acid in H2O. To validate the identity of target
species, analytes were spiked with 1-O-hexadecyl-2-
[2H4]acetyl-glycerophosphocholine (d4-16:0 PAF, 2.5 ng)
in replicate LC-ESI-MS/MS analyses. Under these circum-
stances, 10 μl of diluted analyte was added to 5 μl of
standard (2.5 ng) and brought to 40 μl with 0.1% formic
acid in H2O. Samples were loaded onto a 96-well sam-
pling plate, covered with a pre-slit well cap, and ther-
mostated at 4°C. A micro flow 1100 HPLC system
(Agilent, Palo Alto, CA) introduced the analytes onto a
200 um × 50 mm pre-column packed with 5 μm YMC
ODS-A C18 beads (Waters, Milford, MA) at a flow rate of
10 μl/min in a 2000 Q TRAP mass spectrometer. The sol-
vents used were water and acetonitrile each with 0.1% for-
mic acid (J.T. Baker, Phillipsburg, NJ). The HPLC flow was
split and the analyte was eluted through a 75 um × 50 mm
picotip emitter (New Objective, Woburn, MA), interfaced
with the mass spectrometer via electrospray ionization, at
~200 nL/min. The emitter was packed with the same
beads as those of the pre-column. A linear gradient was
used to separate glycerophospholipid species. The gradi-
ent of the HPLC increased from 5% to 30% acetonitrile in
2 minute, from 30 to 60% acetonitrile in 7 minute, from
60% to 80% acetonitrile over the next 33 minutes, and
from 80% to 95% acetonitrile over the next 4 minutes.
Data were collected on a 2000 Q-TRAP mass spectrometer
operated with Analyst 1.4.1 (Applied Biosystems/MDS
Sciex, Concord, ON). Total glycerophospholipids
between m/z range of 450 to 600 were analyzed by
enhanced MS scan. Specific glycerophosphocholine spe-
cies were further analysed in positive ion mode using pre-
cursor ion scan for an MS/MS fragment with a mass to
charge ratio (m/z) of 184.0, a diagnostic fragment of
phosphocholine [18]. Extracted ion chromatogram (XIC)
generated peak areas of LC-MS/MS data measured using
Analyst 1.4.1 (Applied Biosystems/MDS Sciex). Peak areas
were normalized to the spiked internal standard to stand-
ardize between MS runs and to control for variation in
extraction efficiency. Individual species were identified
based on theoretical mass validated by closer examination
of retention time and following spiking with deuterated
standards.
Results
Cytosol modulates α-syn membrane binding
To identify novel co-factors of α-syn binding to presynap-
tic membranes, we assessed whether co-incubation with
brain cytosol modifies α-syn's interaction with mem-BMC Neuroscience 2008, 9:92 http://www.biomedcentral.com/1471-2202/9/92
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branes. Our assay measured the binding of recombinant
human α-syn purified from E. coli to synaptic membranes
prepared from brains of α-syn-deficient (KO) mice, in the
presence or absence of brain cytosol derived from α-syn-
deficient mice (Figure 1A). We first analysed α-syn bind-
ing to synaptic membranes in the presence or absence of
cytosol. As shown in Figure 1B, the binding of α-syn, with
or without familial PD-linked mutations, was signifi-
cantly improved by co-incubation with cytosol. Despite
the deficient membrane binding of A30P as compared to
that of Wt and A53T, all three forms of α-syn showed
increased binding over a 30-fold range in concentration,
with a pronounced augmentation of binding in the pres-
ence of cytosol (Figure 1C). The ratio of bound/unbound
α-syn was higher at lower α-syn concentrations. These
results suggest that endogenous cytosolic factors becom-
ing limiting with increasing α-syn and can partially coun-
terbalance the otherwise impaired binding induced by the
A30P mutation.
Characterization of cytosol action on α-syn binding
We recently reported that the dissociation of the α-syn
from synaptic membranes requires cytosolic proteins as
defined by sensitivity to proteases. To further characterize
cytosol action on α-syn binding, and because the data in
Fig 1C suggests that cytosol activity becomes saturated at
high α-syn concentration, we analysed α-syn binding with
varying cytosol concentrations over a 6-fold range that we
have previously shown to be effective in mobilizing
reserve neurotransmitter from permeabilized synapto-
somes [19] (Figure 2A). In accord with the data in figure
1B, both Wt and A30P α-syn binding was strongly up-reg-
ulated by increasing cytosol concentration, whereas only
high cytosol concentration resulted in increased A53T α-
syn binding. To determine whether the cytosolic factors
act on α-syn or on the acceptor synaptic membranes, we
first pre-incubated α-syn or synaptic membranes sepa-
rately with KO cytosol. The membranes were subse-
quently washed briefly to remove unbound cytosolic
factors. As shown on Figure 2B, exposure of the mem-
branes alone to cytosol was sufficient to potentiate α-syn
binding, which was equivalent to α-syn binding to mem-
branes in the presence of cytosol. These results suggest
that cytosolic activity can be mediated by affecting the
acceptor membrane rather than soluble α-syn.
To determine the nature of the cytosolic factor(s), we
assessed whether activity was affected by pre-digestion of
cytosolic proteins by trypsin- or proteinase K-mediated
proteolysis (Figure 2C). Digestion of cytosol was termi-
nated by trypsin inhibitor and PMSF prior to incubation
with α-syn and synaptic membranes, and the extent of
proteolysis was verified by Coomassie blue stain (not
shown). Although, no significant differences between
undigested and digested cytosol were observed for either
Wt or A53T α-syn binding, the A30P mutant showed sig-
nificantly reduced binding in the presence of protease-
treated cytosol, reaching a basal level similar to the con-
trol condition in absence of cytosol. This suggests that the
A30P mutation confers a unique dependence on cytosolic
protein(s) required to mediate α-syn interactions with
synaptic membranes. Moreover, comparable levels of a
non-specific protein, bovine serum albumin (BSA), did
not affect A30P α-syn binding to synaptic membranes
(data not shown), suggesting that A30P α-syn binding
depends on specific cytosolic proteins.
Involvement of cytosolic lipids in α-syn membrane binding
Because Wt and A53T α-syn appear to require protease-
insensitive cofactors for membrane binding, and α-syn
conformation is known to be affected by lipids (Jo et al.
2002), we examined whether removal of cytosolic lipids
by chloroform extraction can alter the proportion of α-syn
able to bind synaptic membranes (Figure 3A). We
observed that the binding of Wt α-syn and PD-linked
mutants were decreased in the presence lipid-deficient
cytosol, suggesting a role for cytosolic lipids in the bind-
ing of α-syn to synaptic membranes. These results are also
consistent with our observation that heat-denatured
cytosol retains its activity to potentiate Wt and A53T α-syn
binding (data not shown). Moreover, consistent with the
results in Fig 1B showing that A53T α-syn membrane
binding is less dependent on cytosol, it was also the least
affected by lipid extraction. It is also important to note
that the chloroform extraction did not non-specifically
denature cytosolic proteins because the protein-contain-
ing fraction partially rescued A30P α-syn binding, in
accord with its dependence on a protease-sensitive
cytosolic component.
Several studies have noted significant changes in brain lip-
ids, notably in the metabolism of neutral brain lipids, in
α-syn-deficient animals [20-22]. Therefore, to test
whether our results are specific to KO cytosol we com-
pared human α-syn binding in the presence of KO cytosol
or cytosol derived from nontransgenic animals with nor-
mal α-syn expression. In order to detect only the exoge-
nously added human α-syn, and not endogenous murine
α-syn present in normal cytosol, we used the human α-
syn specific monoclonal antibody 211. We observed no
significant differences in cytosol-dependent α-syn bind-
ing when KO versus normal cytosol was used (Figure 3B).
We used LC-ESI-MS to identify lipid cofactors present in
α-syn KO cytosol. Because previous studies have indicated
that the strongest lipid interactions with α-syn are with
either neutral or anionic phospholipids [3,8,23,24], we
focused our initial analysis on the glycerophosphocholine
species present in KO cytosolic extracts [18] as the detec-
tion methodologies are well-established in our laboratoryBMC Neuroscience 2008, 9:92 http://www.biomedcentral.com/1471-2202/9/92
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Effect of cytosol on binding α-syn Figure 2
Effect of cytosol on binding α-syn. (A) Recombinant α-syn (Wt, A30P and A53T) were incubated in presence of different 
concentrations of KO cytosol (0.5, 1.5, and 3 mg/ml), for 10 min at 37°C. Compared to the control condition (without 
cytosol), all cytosol concentrations had a significant effect on Wt and A30P α-syn binding, but only the highest concentration of 
cytosol had a significant effect on A53T α-syn binding (One way ANOVA test, p < 0.0001, Bonferroni's multiple comparison 
post-test). (B) KO synaptic membranes and α-syn were pre-incubated for 15 minutes at room temperature with KO cytosol. 
Membranes were then centrifuged at 14000 × g and washed with KOAc buffer to remove unbound factors. Binding of purified 
α-syn to KO membranes in the absence of cytosol (ctrl) was compared to its binding to cytosol-treated membranes without 
added cytosol (memb), and to cytosol-treated α-syn incubated with KO membranes (α-syn). No significant difference was 
observed between the two pre-incubated condition (Student T-test, p > 0.05). (C) KO cytosol was pre-incubated with trypsin 
or proteinase K for 15 min at 37°C. Enzymes were then respectively inactivated with trypsin inhibitor and PMSF for 10 min at 
room temperature. Compared to the cytosol condition (cyt) which, as a control, was incubated with the enzyme pre-inacti-
vated by the inhibitor, only A30P α-syn binding was significantly affected by the cytosolic protein digestion (Student T-test, p < 
0.0001), whereas no significant differences were observed for Wt and A53T proteins (Student T-test, p > 0.05).BMC Neuroscience 2008, 9:92 http://www.biomedcentral.com/1471-2202/9/92
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Effects of cytosolic lipid depletion on α-syn binding Figure 3
Effects of cytosolic lipid depletion on α-syn binding. (A) Using chloroform extraction to fractionate cytosol into three 
fractions: the top fraction contains the gangliosides or small organic polar molecules, the interface layer contains the proteins 
and the bottom phase contains lipids solubilised in chloroform. We incubated the synaptic membrane with the two lipid free-
fractions, top and interphase (protein) layers, in presence of recombinant α-syn. The lipid-free fractions did not show any sig-
nificant effects on the Wt and A53T α-syn binding compared to the control condition (α-syn incubated with synaptic mem-
branes in absence of cytosol; Student T-test, p > 0.05) while the A30P α-syn binding was increased (compared to control 
condition, Student T-test, p < 0.01). (B) Recombinant α-syn (Wt, A30P and A53T) were incubated with synaptosomal mem-
branes in the presence of 1.5 mg/ml cytosol from either KO mice (KO) or from non-transgenic mice (nonTg) for 10 min at 
37°C. Binding of normal and mutant human α-syn, measured by the human α-syn specific monoclonal antibody 211, is normal-
ized to that of Wt α-syn in the presence of KO cytosol. (C) Recombinant Wt α-syn was incubated with synaptosomal mem-
branes and C16:0 PAF (0, 10, 100 nM) in the absence (open bars) or presence of delipidated cytosol (closed bars). Inclusion of 
100 nM C16:0 PAF significantly increased α-syn binding only in the presence of the delipidated cytosol (compared to corre-
sponding condition without C16:0 PAF, Two-Way ANOVA, p < 0.01, Bonferroni's multiple comparison test p < 0.01, n = 3).BMC Neuroscience 2008, 9:92 http://www.biomedcentral.com/1471-2202/9/92
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[16]. As our extracts are dialyzed prior to testing, these
lipid species are predicted to be in complexes with pro-
teins greater than 12 kDa. Choline-containing lipids
extracted from these complexes were separated and spe-
cies with a mass to charge ratio (m/z) between 450 and
600 identified by MS scan for a protonated molecule at
expected m/z followed by positive ion mode precursor
ion scan for a phosphocholine product ion at m/z 184
[16]. Twenty-four candidate species were identified in the
extracted ion chromatographs (Table 1). Because α-syn is
known to play a role in regulating lipid metabolism in
brain, notably in the regulation of the glycerophospho-
choline fatty acid turn over, [21,22,25,26], we compared
this profile to the lipids detected in Wt cytosol. We found
that Wt cytosol contained the same glycerophospho-
cholines as KO preparations with the exception of two
species detected de novo (Table 1). The overall abundance
of the majority of small second messenger species was ele-
vated in KO cytosol relative to Wt.
To identify glycerophosphocholines interacting directly
with α-syn in our binding assays, we performed two com-
plementary analyses. First, we immunoprecipitated α-syn
from Wt cytosol and identified the glycerophospho-
choline present in protein complex after dialysis by LC-
ESI-MS. Second, we incubated recombinant α-syn with
KO cytosol and identified lipid binding partners follow-
ing immunoprecipitation. Non-specific lipid binding was
assessed by lipid analysis of immunoprecipitates for α-syn
from KO cytosol. Data are expressed as fold change in
lipid abundance above background (Table 1). Only two
predicated species exhibited significant association with
Wt and Wt recombinant α-syn: C14:0 PAF and C16:0 PAF.
C16:0 PAF was definitively identified by based on its co-
elution with d4-C16-PAF (m/z 528.7) (data not shown).
Table 1: Elution time and parent ion masses of candidate glycerophosphocholine species bound to proteins in dialyzed α-synuclein KO 
cytosolic extracts identified by LC-ESI-MS
Parent ion mass (± 0.15 m/z)a LC elution time (± 0.4 min)a Lipid species in complex with 
proteins in KO cytosolb
Species abundance 
relative to Wt (Fold 
change)
Species bound to α-syn follow-
ing immunoprecipitation (Fold 
change above non-specific 
binding)c
494.7 12.29 C14:1-PAF ↑-fold
12.89 C16:1-LPC No change
496.8 13.79 C14:0-PAF ↑3-fold ↑9.2x
14.39 C16:0 LPC ↑2-fold ↑9.8y
520.7 13 C16:2-PAF ↑2-fold
13.41 C18:2-LPC No change
522.8 14.66 C16:1-PAF ↑5-fold
15.15 C18:1-LPC ↑2-fold
524.9 17.2 C16:0-PAFc ↑2-fold ↑1.7x
18.11 C18:0-LPC ↑4-fold ↑2.3y
545 C18:4-PAF ↑11-fold
13.12 C20:4-LPC
545.9 13.11 C18:3-PAF De novo detection
13.99 C20:3-LPC
568.8 13.12 C20:6-PAF ↑4-fold
C22:6-LPC
581 15.32 C20:0-PAF ↑17-fold
16.04 C22:0-LPC ↑12-fold
594 16.52 C24:7-LPC ↑2-fold
C22:7-PAF
23:7c
24:7d
C20:0-acyl-PAF
C24:0-lysoPAF
a Variations between m/z and retention time between runs were established for all glycerophospholipid species and respresents mean ± standard 
deviation.
b Identification is predicted based on the theoretical monoisotopic mass values. CX:Y refers to the number of carbon atoms and double bonds in the 
sn-1 chain with a predicted acetyl (PAF) or hydroxyl (LPC) group at the sn-2 position. Only the most likely species are indicated although multiple 
isoforms may be present with the double bond in the alkyl chain at different positions. Isobaric species with same m/z eluting at different times were 
not further distinguished with the exception of C16:0 PAF.
c Replicate experiments were performed in which α-syn was immunoprecipitated from Wt cytosolx or recombinant α-syn was added to KO 
cytosoly. Immunoprecipitates were analysed by LC-ESI-MS. Data represent mean increase in relative abundance above background (non-specific) 
signal ± standard deviation as described in Materials and Methods.
d Identity verified by based on its coelution with d4-C16-PAF spiked at time of analysis.BMC Neuroscience 2008, 9:92 http://www.biomedcentral.com/1471-2202/9/92
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C14:0 PAF was identified based on retention time and
monoisotopic mass values. Definitive identification was
not possible in the absence of a commercially available
synthetic standard of suitable purity. To validate effects of
C16:0 PAF on α-syn membrane interaction, we tested
whether C16:0 PAF enhanced α-syn binding to synaptic
membranes directly (Fig 3C). Incubation of α-syn with
C16:0 PAF alone did not affect α-syn membrane binding.
However, when C16:0 PAF was added in combination
with delipidated cytosol, α-syn binding was significantly
increased. This data are suggestive of a protein-lipid com-
plex required to enhance α-syn's capacity to interact with
neuronal membranes. Specificity was tested using C16:0
lyso-PAF that differs from PAF by the presence of an
hydroxyl group in place of an acetyl group at the sn-2 posi-
tion. C16:0 lyso-PAF was not detected by LC-ESI-MS anal-
ysis in complex with protein in KO cytosol or α-syn
immunoprecipitates and did not enhance α-syn mem-
brane binding alone or in combination with delipidated
cytosol (data not shown).
A30P Parkinson's disease-linked mutation interacts 
differently with synaptic membranes compared to Wt
Our results above, though consistent with previous
reports showing that the A30P mutation impairs mem-
brane binding ability compared to Wt and A53T α-syn,
notably indicate that A30P α-syn binding is also signifi-
cantly enhanced by cytosol, albeit not to the extent of Wt
α-syn. Because α-syn is prone to self-aggregation and
changes to the secondary structure of α-syn could induce
artifactual differences between Wt, A53T and A30P mem-
brane binding, we assessed whether each of the α-syn pro-
teins are structurally similar in their soluble form prior to
exposure to membranes, and not dimerized or aggregated
which could affect membrane binding ability. All three α-
syn proteins eluted in the same fractions as monomers
from a size-exclusion column, and their circular dichr-
oism spectra showed the characteristic minima of a ran-
domly structured protein near 200 nm (Figure 4).
Previous in vitro studies using artificial or cellular mem-
branes showed that α-syn interacts with lipids and prefer-
entially associates with lipid raft fractions isolated from
cultured HeLa cells or synaptic vesicles [27,28]. Moreover,
in those studies the A30P mutation impaired interaction
with rafts, and consequently, with the membrane. Because
those studies evaluating α-syn membrane binding did not
assess cytosolic co-factors that could ostensibly regulate α-
syn behaviour in vivo, we analysed the proportion of puri-
fied α-syn recovered with the lipid raft fractions following
binding in the presence or absence of KO cytosol (Figure
5A). In contrast to the previous report [28], we found that
very little exogenously-added α-syn (< 5%) co-eluted with
the flotillin-positive lipid raft fractions, and this was not
affected by the presence of cytosol, although α-syn immu-
noreactivity in other fractions (6–9) was increased by
cytosol. These results indicate that the cytosol-dependent
change in α-syn membrane binding was not due to
increased association with lipid rafts, and the A30P α-syn
was not less likely to co-elute with flotillin-rich fraction
than either Wt or A53T α-syn.
To assess whether endogenously expressed cytosolic fac-
tors might play a role in regulating α-syn association to
lipid rafts in vivo, but are not fully reproduced in our in
vitro assay, we also quantified the amount of α-syn that
co-elutes with flotillin-1 in synaptosomes from brains of
human α-syn Tg mice. Only a minor fraction of total α-
syn co-eluted with the lipid raft fraction from mouse brain
synaptosomes (Figure 5B) or from whole brains (not
shown), and we observed no significant differences
between both PD mutants and Wt α-syn. Thus, mouse
brain-expressed A30P α-syn appears to show a similarly
weak distribution (< 5%) to gradient fractions containing
lipid raft marker flotillin-1 as Wt and A53T α-syn.
We also considered the possibility that the lower binding
of A30P α-syn to total membranes is due to a transient or
low affinity interaction that is not stable during isolation.
To test this hypothesis, we assessed whether covalent
cross-linking using paraformaldehyde after different incu-
bation periods with purified A30P α-syn might stabilize
the bound α-syn. Under these conditions, cross-linking
increased α-syn association at t = 2, 3 and 5 minutes (Fig-
ure 5C). This additional α-syn was mostly excluded from
the gradient fractions containing lipid rafts (Figure 5D)
suggesting that the α-syn binding to membranes may be
stabilized by other membrane proteins but not those asso-
ciated with lipid rafts. Similar to the A30P mutant, Wt and
A53T α-syn binding to membrane was also increased by
cross-linking (Fig 5E). However, maximal binding of the
Wt α-syn occurred in the first minute and remained stable
thereafter. The binding of A53T mutant also peaked in
first minute, but then slowly declined. Thus, the binding
kinetics of α-syn bearing either PD-linked mutation sug-
gest a more transient membrane interaction.
α-Syn interaction with synaptic membrane is regulated by 
ATP
α-Syn membrane attachment may be regulated by nerve
terminal activity initiated by membrane depolarization
[27], a process which results in Ca2+ influx, and elevated
metabolic energy consumption. Therefore, we tested
whether the addition of Ca2+ and ATP influenced α-syn
binding. Our results show that ATP, but not ATPγS, signif-
icantly increased the level of membrane bound Wt α-syn
and PD-linked mutants in the absence or presence of KO
cytosol, whereas Ca2+ had no affect the α-syn binding (Fig-
ure 6A–C). The effect of ATP was additive to cytosol action
suggesting that they act independently, and this was sup-BMC Neuroscience 2008, 9:92 http://www.biomedcentral.com/1471-2202/9/92
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Purified E-coli α-syn is monomeric and unstructured Figure 4
Purified E-coli α-syn is monomeric and unstructured. Each recombinant α-syn (Wt, A30P and A53T) was analyzed by 
size exclusion chromatography to determine the presence of monomeric, dimeric, or other higher order forms. Eluate peaks 
(fraction 27) were then assessed by circular dichroism spectra to define the secondary structure of the α-syn proteins (Inset). 
Far-UV circular dichroism spectra were recorded on an Aviv circular dichroism spectrometer model 62DS (Lakewood, NJ, 
USA) at 25°C using quartz cells with a path length of 0.1 cm. Spectra were obtained from 195 nm to 260 nm, with a 1.0-nm 
step, 1.0-nm bandwidth, and 4-s collection time per step. The experimental data were expressed as mean residue ellipticity (θ) 
(deg·cm2·dmol-1). Only monomeric forms of α-syn where identified by size exclusion chromatography, and all α-syn share sim-
ilar random secondary structure.BMC Neuroscience 2008, 9:92 http://www.biomedcentral.com/1471-2202/9/92
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α-Syn binding to synaptosomal lipid rafts Figure 5
α-Syn binding to synaptosomal lipid rafts. Using a 42-30-5% discontinuous sucrose gradient, we analysed the proportion 
of α-syn that co-localised with flotilin-1, a lipid-raft marker. (A) Less then 5% of α-syn co-eluted with flotillin-1 after binding (in 
vitro) to α-syn KO synaptic membranes, in absence or presence of KO cytosol, and proportionally, no significant differences 
were observed between Wt and PD-linked mutants (Student's T-test, p > 0.05). (B) The proportion of α-syn that co-localised 
with flotillin-1 in vivo, using intact synaptosomes from transgenic mice expressing the human α-syn (Wt, A30P or A53T). As 
observed in vitro, only a small proportion of α-syn co-eluted with lipid rafts and no significant differences were observed 
between Wt and PD-linked mutations (Student T-test, p > 0.05). (C) A30P α-syn was subjected to paraformaldehyde-induced 
cross-linking to potential interacting proteins in synaptic membranes after 1, 2, 3, 5 and 10 minutes of incubation with synaptic 
membranes. A significant increase of bound α-syn after 2, 3 and 5 minutes was observed compared to the control condition 
(without cross-linking) (One-Way ANOVA p < 0.001, Bonferroni's multiple comparison test). (D) The proportion of α-syn 
present in the lipid-raft fraction after cross-linking did not show any significant differences compared to incubations without 
cross-linking (Student t-test: 1 min: p > 0.05; 3 min: p > 0.05). (E) A significant increase of bound Wt and A53T α-syn after 
paraformaldehyde-induced cross-linking was observed compared to the control condition without cross-linking (One-Way 
ANOVA, *p < 0.05, **p < 0.01,***p < 0.001, Bonferroni's multiple comparison test).BMC Neuroscience 2008, 9:92 http://www.biomedcentral.com/1471-2202/9/92
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ported by the fact that ATPγS did not reduce the cytosol-
dependent binding.
Discussion
Aberrant aggregation of α-syn has been detected in an
increasing number of neurodegenerative diseases, now
collectively known as synucleinopathies. These include
Parkinson's disease (PD), Dementia with Lewy bodies
(DLB), Alzheimer's disease (AD), multiple system atro-
phy, and Down syndrome [29]. Accumulations of α-syn
in all these disorders have a common fibrillar configura-
tion, though they differ in the co-localisation with other
proteins including tau, parkin, and synphilin [30]. While
the physiological functions of normal α-syn remain to be
fully elucidated, several studies suggested it may play a
role in synaptic plasticity, regulate dopamine (DA) neuro-
transmission via effects on vesicular DA storage, and act as
a co-chaperone with cysteine-string protein to maintain
nerve terminals [31]. These roles may involve α-syn inter-
actions with proteins in cytosol and on membranes,
though little is known about the α-syn membrane interac-
tion in vivo and how membrane-bound and freely-diffusi-
ble pools of α-syn are maintained. Therefore, to
understand the regulation of α-syn interaction with syn-
aptic membranes, we developed an in vitro assay which
measures the binding of recombinant E. coli-derived α-syn
to α-syn-deficient synaptosomal membranes and recapit-
ulates many features of the interactions observed in vivo.
Using this binding assay, we showed that approximately
60% of the Wt and A53T soluble α-syn interacts with
membrane, whereas only a small amount of the PD-
linked A30P mutant is able to stably bind to the mem-
brane (Figure 1B). Reduced A30P binding has been well-
reported in several studies using artificial membranes [32-
34] and can be explained by the expected disruption of
the α-helix induced by the mutation. Indeed, the second-
ary structure of α-syn is divided into an α-helical lipid-
binding amino-terminal and an unstructured lipid-free
carboxyl-terminal [35]. The replacement of an Ala by a
Pro in the A30P variant restricts the conformational space
available to the preceding residue, Ala29, implying the
loss of two intra-helical hydrogen bonds modifying the
backbone structure of the protein, while the backbone
structure and dynamics of the A53T α-syn mutant is found
to be virtually unchanged from the Wt [36].
Despite the predicted structural limitations induced by
the A30P mutation, and its impaired membrane binding
capacity noted in in vitro assays, we showed previously
that the amounts of Wt, A53T, and A30P α-syn that segre-
gate with synaptic membrane fractions derived from
mouse brains are not significantly different [14]. These
disparate findings suggest that additional factors in vivo
control α-syn membrane binding and can be reconciled
by our present results showing that the addition of mouse
brain cytosol stimulated the membrane association of Wt
and A53T α-syn and partially rescued the intrinsically
poor binding of the A30P α-syn. These data provide evi-
dence that the subcellular proportion of membrane-
bound and soluble α-syn may be regulated by cytosolic
factors in vivo, which are far more concentrated (~300 mg/
ml) than the 0.5–3 mg/ml cytosol used in our assay, and
(A-C) Recombinant α-syn (Wt, A30P and A53T) were incu- bated with ATP (1 mM), ATPγS (3 mM), Ca2+ (1 mM), ATP/ Ca2+ or ATPγS/Ca2+ in absence or presence of 1.5 mg/ml of  KO cytosol, for 10 min at 37°C Figure 6
(A-C) Recombinant α-syn (Wt, A30P and A53T) were incu-
bated with ATP (1 mM), ATPγS (3 mM), Ca2+ (1 mM), ATP/
Ca2+ or ATPγS/Ca2+ in absence or presence of 1.5 mg/ml of 
KO cytosol, for 10 min at 37°C. Incubation with ATP (Stu-
dent's T-test, p < 0.001), but not ATPγS or Ca++ (Student's 
T-test, p > 0.05), induced a significant increase in the binding 
of Wt and mutant forms of α-syn (compared to control con-
dition without added cofactors).BMC Neuroscience 2008, 9:92 http://www.biomedcentral.com/1471-2202/9/92
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might compensate for the low A30P α-syn membrane
association observed in vitro.
Surprisingly, we observed that pre-exposure of mem-
branes to cytosol was sufficient to augment subsequent α-
syn binding, suggesting a mechanism whereby mem-
branes can be primed by cytosolic factors for α-syn recruit-
ment. Moreover, unlike the cytosolic protein requirement
for the dissociation of α-syn from synaptic membrane
[14], the cytosol-dependent component of α-syn binding
is resistant to digestion by proteinase K and trypsin for the
Wt and A53T α-syn, though not for A30P α-syn. This sug-
gests that although cytosolic proteins are not required for
the Wt and A53T α-syn membrane interaction, α-syn with
A30P mutation would require protein assistance. As it is
unlikely that a specific protein interaction evolved to spe-
cifically maintain A30P α-syn binding, the protein inter-
action implied by our results may also interact with Wt α-
syn as well, though it is not essential for its membrane
binding. We previously reported that cytosolic proteins
are required for the dissociation of membrane-bound α-
syn [14], presumably by transient association with α-hel-
ical conformation of α-syn on lipid bilayers. The same fac-
tor(s) may also aid in the reverse reaction by coordinating
the A30P α-syn amino terminal to configure into an
amphipathic α-helix so as to overcome its conformational
limitations or to stabilize the mutant in closer apposition
to the lipid bilayer prior to membrane binding. Such a
mechanism could also account for the transient interac-
tion we observed for A30P mutant with the membrane
fraction. By briefly inducing covalent cross-links at vari-
ous times to stabilize bound α-syn, we observed that
A30P α-syn binding was biphasic, peaking at 3 min and
declining thereafter. It is important to note this was not
due to non-specific cross-linking because the later incuba-
tion periods (i.e. 10 min) did not show increased recovery
of A30P α-syn with membranes despite the substantial
soluble A30P α-syn. These results suggest that α-syn mem-
brane binding may be partially coordinated by local syn-
aptic vesicle proteins. Indeed, proteins such as cysteine
string protein or members of the Rab family may fulfil this
role [31,37,38]. Cross-linking also increased the recovery
of bound Wt and A53T α-syn, although the kinetics were
different from the A30P mutant. Both Wt and A53T bind-
ing peaked in the first minute of incubation suggesting a
quicker interaction with synaptic membranes. Interest-
ingly, the Wt α-syn remained stably associated even when
cross-linking was activated after 10 min of incubation, the
A53T binding declined slowly. These results are consistent
with our previous report [14] showing greater cytosol-
dependent dissociation of both PD mutants from synaptic
membranes.
In the course of characterizing the protein-dependence,
we noted that lipid-depleted cytosol lost its activity to
induce α-syn binding. Because the cytosol used in these
experiments is dialyzed using membranes with a 12 kDa
molecular weight cut-off, only lipid-protein complexes
larger than 12 kDa are retained. These results suggested
that protein-bound polar lipids are likely the protease-
insensitive cytosolic components responsible for assisting
the membrane binding of α-syn. In accord with the con-
formational model of α-syn [39,40] whereby it acquires a
folded helical structure in the N-terminal region in its
membrane-bound state, our results suggested that endog-
enous cytosolic lipids transferred to membranes prior to
α-syn recruitment or bound directly to cytosolic α-syn
may aid α-syn folding at the lipid-cytoplasm interface so
it is more amenable to binding directly to synaptic mem-
branes. To provide further insight into this novel protein-
lipid-protein interaction, we profiled glycerophospho-
cholines bound to proteins in α-syn-deficient cytosol by
nanoflow LC-ESI-MS and precursor ion scan. Our analysis
identified 24 species that can potentially affect α-syn
membrane interactions. While this number clearly under-
estimates the cytosolic lipid content in vivo given our MS
analyses were limited to polar glycerophospholipids with
an m/z between 450 and 600, of which glycerophospho-
choline-containing species were further analyzed, these
data represent the first profile of candidate lipid interac-
tors at the molecular level responsible for the enhanced α-
syn binding. Further, we demonstrated that two glycero-
phosphocholines C14:0 PAF and C16:0 PAF interact with
α-syn, with C16:0 PAF definitively identified at the molec-
ular level. Importantly, C16:0 PAF was able to rescue the
ability of delipidated cytosol to potentiate α-syn mem-
brane binding but did not, in and of itself, enhance α-syn
interaction with membranes. This result suggests the
involvement of a cytoplasmic protein, and although
appears inconsistent with data in Fig. 2C showing that α-
syn binding does not require intact cytosolic proteins, a
more likely possibility is that a cytoplasmic protein may
be required to activate or modify the exogenously added
lipid. For example, binding to GM2 activator protein elic-
its a conformational change in PAF [41]. Arguably, endog-
enous PAF in brain cytosol would be active prior to the
cytosol depletion, and thus delipidation, but not protein
depletion, would impact a-syn binding. Similarly, addi-
tion of exogenous PAF, presumably in an inactive confor-
mation, would need prior activation by delipidated
cytosol. These findings are also consistent with previous
studies indicating that α-syn does not directly bind to pal-
mitic acid (C16:0) [25], yet addition of 1,2-palmitoylole-
oylphosphatidylcholine to α-syn containing protein
lysates promotes self-association and formation of pro-
tein complexes [24]. Here, we further confirmed specifi-
city of these interactions using C16:0 lyso-PAF. C16:0 lyso-
PAF did not impact α-syn interaction with neuronal mem-
branes. Clearly, the nature of these protein-protein-lipid
complexes and their effects on α-syn binding to synapticBMC Neuroscience 2008, 9:92 http://www.biomedcentral.com/1471-2202/9/92
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membranes will require further investigation and expan-
sion of the analysis of lipid co-factors beyond the small
second messenger neutral glycerophosphocholines tested
in this study. Careful analysis of these lipids will also be
relevant to aging and neurodegeneration because abun-
dant data suggest that cumulative oxidative modification
of biomolecules, including lipids, plays an important role
in aging, and free radical damage to brain lipids is
involved in neuronal death in neurodegenerative disor-
ders [42]. There is also accumulating evidence that α-syn
deficiency has complex effects on brain lipid metabolism
and production of lipid second messengers although the
underlying mechanisms are poorly understood
[20,21,25]. Consistent with these data, we also detected
differences in PAF and LPC glycerophosphocholine levels
between KO and normal cytosols, but these did not
impact α-syn binding in our assay. Altogether, our data
suggest that brain-lipids regulate α-syn binding, and an
imbalance in specific species could mediate α-syn accu-
mulation in the cytosol leading to fibril formation.
Despite previous studies suggesting that α-syn preferen-
tially binds to lipid rafts in HeLa cells and to purified lipid
raft fractions from rodent brain [27,28], we were unable
to corroborate this interaction in our studies. We found
that < 5% of total exogenously added α-syn co-eluted with
the lipid raft marker flotillin-1, and this was unaffected by
PD-linked mutations. Moreover, the same minor propor-
tion of brain-expressed α-syn co-eluted with the flotillin-
1 enriched fractions isolated from synaptosomes or whole
brain, ostensibly reflecting negligible lipid raft associated
α-syn in vivo. This low level of brain α-syn in lipid rafts
was also noted by Fortin et al. [27], though they postu-
lated that α-syn may dissociate from brain lipid rafts dur-
ing the biochemical isolation. However, this explanation
is inconsistent with the high recovery of overexpressed α-
syn in lipid rafts from HeLa cells following the identical
isolation procedure [27], and with our results showing
that chemical cross-linking of A30P α-syn stabilized its
membrane association, though not to lipid raft fractions.
Two other explanations could account for the difference
in the earlier studies and ours: First, lipid rafts in HeLa
cells likely have a distinct lipid and protein composition
compared to those in mammalian nerve terminals, possi-
bly allowing them to bind overexpressed α-syn, which is
not normally expressed in HeLa cells. Second, in the
present work, lipid raft fractions were isolated only after
α-syn was incubated with permeabilized synaptosomes,
which retain sufficient internal architecture as to permit
Ca2+-dependent exocytosis [19,43,44]. In contrast, the
study by Kubo et al. [28] isolated lipid rafts before incu-
bating with exogenous α-syn. The biochemical purifica-
tion with 1% TX-100 likely modifies lipid rafts by altering
lipid packing and/or loss of peripherally attached constit-
uents, conceivably affecting subsequent α-syn binding
capacity that is not normally present in vivo.
Because calcium influx and metabolic energy are both crit-
ical for the normal function of nerve terminals, we exam-
ined whether α-syn binding can be affected by
modulating the availability of either Ca2+ or ATP. We
observed that α-syn binding has an ATP-dependant com-
ponent that was not supported by ATPγS, and is insensi-
tive to calcium. Because the increased α-syn binding in the
presence of ATP and cytosol were additive and ATPγS did
not affect cytosol-induced α-syn binding, it is likely that
ATP and cytosolic factors act independently. One possibil-
ity is that ATP acts on a membrane protein whose interac-
tion with membrane-bound α-syn is stabilized by
chemical cross-linking, whereas cytosolic lipids modulate
α-syn conformation either by direct interaction in cytosol
or after intermediate transfer to a membrane component.
Our results suggest that changes in synaptic ATP levels due
to elevated metabolic consumption during exocytosis
could modulate the α-syn solubility and may explain how
neuronal depolarization can increase the level of freely-
diffusible cytoplasmic α-syn in a Ca2+-independent man-
ner [45]. The ATP sensitivity is also relevant to aging
because neurodegenerative diseases are commonly associ-
ated with mitochondrial dysregulation and consequent
impairment of energy production[46]. Under such patho-
logical conditions, it is possible that lowered ATP levels
may increase the cytosolic α-syn, which is significantly
less constrained structurally than the membrane bound
form. Concomitant oxidative stress could thereby pro-
mote β-sheet formation and accelerate α-syn aggregation.
Conclusion
In conclusion, while the identities of the cytosolic compo-
nents that assist the membrane interaction of α-syn
remain to be fully characterized, our study reveals that
cytosolic lipids and ATP are two of the principal factors
regulating α-syn interaction with synaptic membranes. In
addition, the relatively poor membrane binding of A30P
α-syn could be explained by a more transient interaction
with synaptic membrane and was partially rescued by the
presence of protease-sensitive factors in brain cytosol.
Those results suggest that endogenous brain proteins
moderate the otherwise inefficient membrane association
of A30P α-syn mutant, and represent a potential targets to
influence α-syn solubility in brain.
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